Voyager Therapeutics (VYGR) Assets (2014 - 2026)

Voyager Therapeutics has disclosed Assets across 13 years of filings, most recently posting $219.3 million for Q1 2026.

• Assets for Q1 2026 came in at $219.3 million, down 37.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $219.3 million (down 37.91% YoY), and the FY2025 annual result was $252.3 million, down 35.81% from the prior year.
• Assets came in at $219.3 million for Q1 2026 at Voyager Therapeutics, down from $252.3 million in the prior quarter.
• In the past five years, Assets ranged from a high of $469.6 million in Q1 2024 to a low of $159.4 million in Q4 2022.
• The 5-year median for Assets is $315.5 million (2023), against an average of $306.6 million.
• Across the five-year window, Assets soared 120.44% in 2023 and sank 37.91% in 2026, its largest moves.
• Voyager Therapeutics' Assets stood at $159.4 million in 2022, then jumped by 120.44% to $351.3 million in 2023, then gained by 11.89% to $393.0 million in 2024, then plunged by 35.81% to $252.3 million in 2025, then fell by 13.06% to $219.3 million in 2026.
• The last three Assets figures came in at $219.3 million (Q1 2026), $252.3 million (Q4 2025), and $288.3 million (Q3 2025), per Business Quant data.